Dexafree

Quick links to important sections

Medically reviewed

Marina Burgos

Last updated on 10/01/2026

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Dexafree

Quick Facts

Property Description
Active ingredient Dexamethasone (as sodium phosphate)
Form Preservative-free eye drops (ophthalmic solution)
Pharmacological class Glucocorticoid (Corticosteroid)
Common use Suppression of ocular inflammation and swelling
Origin Synthetic (fluorinated steroid)

What is the Composition and Class of Dexafree?

Dexafree is an ophthalmic medication containing the potent active substance Dexamethasone, specifically present as Dexamethasone sodium phosphate. This core component is classified within the pharmaceutical field as a Glucocorticoid—a powerful type of synthetic corticosteroid that acts on the body's inflammatory response pathways. Its structure is an analog of naturally occurring cortisol, which grants it enhanced anti-inflammatory activity focused on the eye. Dexamethasone is indicated for the treatment of various inflammatory conditions in ocular therapy.

Preservative-Free Ophthalmic Solution: The Unique Formulation

The medicine is supplied as a sterile, aqueous eye drop solution for ocular administration and is typically classified as a Prescription Only Medicine (POM). A critical distinction of Dexafree is its formulation as a preservative-free product, which is often contained in individual single-dose units (SDU). This preservative-free design is a key differentiating factor, specifically intended to reduce potential damage to the ocular surface often associated with long-term exposure to preservatives found in multi-dose drops. Preservative-free ophthalmic solutions are designed to minimize ocular toxicity, particularly for patients requiring prolonged therapy.

General Purpose: Suppressing Inflammation in the Eye

The primary general purpose of this Dexamethasone preparation is to serve as a strong, locally acting anti-inflammatory agent in the anterior segment of the eye. It operates by potently suppressing the local immune response, helping to resolve inflammatory symptoms following common issues such as trauma or non-infectious conjunctivitis. This fundamental action is essential for rapidly mitigating symptoms associated with acute inflammatory distress, such as pronounced redness, irritation, and excessive tissue swelling (edema), ensuring the stabilization of the sensitive ocular environment.

Regulatory References

  1. EMA Public Assessment Report

What side effects are possible with Dexafree?

Possible Side Effects and Safety Information

This section describes the adverse reactions and safety characteristics of Dexamethasone ophthalmic solution as documented in official government regulatory documents.

Ocular Reactions and Frequency Classification

Official regulatory documents structure the safety profile based on incidence:

  • Very Common (Affecting more than 1 in 10 people): An increase in intra-ocular pressure (IOP) is frequently documented, often observed after two weeks of treatment.
  • Common (Affecting 1 to 10 in 100 people): Expected reactions following instillation include ocular discomfort, stinging, burning, irritation, and transient blurred vision.
  • Uncommon (Affecting 1 to 10 in 1,000 people): Documented risks at lower frequency include posterior subcapsular cataract formation, glaucoma (optic nerve damage), delayed wound healing, and hypersensitivity reactions.

Duration-Related Safety Concerns

The most serious safety concerns are explicitly linked to the duration of exposure. Prolonged or long-term continuous use is associated with an increased risk of developing glaucoma and cataract formation. Furthermore, intensive or long-term continuous therapy carries the rare potential for systemic effects classified as Endocrine disorders, including adrenal suppression and Cushing's syndrome.

Serious Adverse Reactions and Safety Notes

Serious adverse events listed in regulatory labeling include corneal perforation (particularly in patients with pre-existing thinning of the cornea or sclera) and secondary ocular infections. Additionally, specific safety notes are provided for certain populations:

  • Paediatric Patients: The risk of corticosteroid-induced ocular hypertension may occur earlier in children; long-term continuous use is generally avoided.
  • Corneal Integrity: The solution's phosphate content is associated, in very rare cases, with the potential for corneal calcification in patients with significantly damaged corneas.

Overdose and Emergency Response

The official regulatory profile for an overdose of Dexamethasone ophthalmic solution, such as Dexafree, establishes that acute systemic overdose is unlikely due to its low concentration, single-dose unit formulation, and local route of administration. This classification by government health authorities directs the primary focus toward managing potential local effects and adhering to mandated help-seeking actions.

A documented manifestation of excessive local exposure is the risk of a rise of intraocular pressure (IOP). Should this clinical sign occur, the official prescribing information mandates that the treatment must be discontinued. The primary physical action described for local excess is that the solution may be wiped away with a clean tissue from the eye and surrounding area.

When to Seek Urgent Medical Help

Regulatory guidelines are explicit regarding emergency response. Patients are required to seek medical attention immediately at the first appearance of any adverse drug reaction. While acute systemic effects are rare, the potential for significant systemic absorption, which carries the risk of adrenal suppression, is noted in cases of consistently high dosages or when the medicine is used in extended paediatric therapy. The overall profile is defined by these local risks and regulator-mandated help-seeking triggers.

Therapeutic Uses of Dexafree

What Dexafree Treats: Main Uses and Benefits

Dexafree (Dexamethasone ophthalmic solution) is commonly used in situations involving inflammatory or irritative states of the eye, where additional symptomatic support is needed. It provides supportive relief that helps ease the overall symptom burden. This therapeutic domain is considered relevant for its action on the eye's front structures.

The medication may be part of symptomatic management across therapeutic domains, including inflammation of the cornea, conjunctiva, iris (iritis), and ciliary body (cyclitis). It is also relevant in conditions characterized by periods of heightened symptoms, such as severe allergic conjunctivitis or inflammatory episodes associated with Herpes zoster keratitis and clinical situations that follow eye surgeries.

“The primary goal of this therapy is to assist with easing the overall symptom load and support the patient during difficult episodes of heightened discomfort.”

The medication is relevant for easing symptom clusters that may become intense or disruptive, including eye pain, burning sensation, irritation, and noticeable physical signs like excessive redness and swelling.

Quick Fact: Relief for Acute Ocular Discomfort
Relevant Symptom Focus Pain, irritation, redness, swelling (edema)
Applicable Clinical Contexts Clinical situations that follow surgery and acute non-infectious inflammation
Supportive Benefit Helps maintain a sense of stability during temporary periods of stress

Eligibility and Restrictions for Use

The eligibility profile for Dexafree (Dexamethasone ophthalmic solution) is strictly governed by regulatory classifications, defining absolute contraindications and conditional use.

  • Absolute Contraindications (Do Not Use): Use is strictly prohibited in patients with known hypersensitivity to the medicine. It is also contraindicated in cases of active, untreated viral, fungal, or mycobacterial eye infections (such as epithelial Herpes Simplex Keratitis), and in patients with compromised ocular structural integrity, including unhealed corneal ulcers or perforations.

  • Age and Approval Status: Efficacy and safety have not been established in the pediatric population. Long-term continuous use in children must be avoided due to the risk of adrenal suppression. The medicine is not recommended during pregnancy as a precautionary measure, although it can be used during lactation. Adults and the elderly are the primary eligible populations, with older adults requiring close ophthalmic monitoring.

  • Conditional Use and Restrictions: Use is conditional in patients with pre-existing conditions like glaucoma or a history of steroid-induced high intraocular pressure (IOP); mandatory, frequent IOP monitoring is required for these groups. Patients with diabetes must inform their ophthalmologist. Furthermore, contact lenses must not be worn during the use of this eye drop solution.

What should I know about interactions with other medicines?

The official regulatory documents for this ophthalmic solution outline specific interaction patterns, primarily concerning metabolic interference and administration requirements.

Documented Drug-Drug Interactions

Interaction Type Interacting Medicines Official Regulatory Statement
Systemic Exposure Increase (Pharmacokinetic) Ritonavir and cobicistat (CYP3A4 Inhibitors) Co-administration may decrease dexamethasone clearance, leading to increased systemic exposure to the corticosteroid.
Local Ocular Interaction (Pharmacodynamic) Phosphate-containing topical beta-blockers (e.g., certain eye drops for high pressure) Combined use has been reported to cause superficial stromal corneal precipitations (calcium phosphate crystals) in the eye.

Timing and Population Restrictions

When co-administered with other eye drops or ophthalmic solutions, a mandatory administration timing separation is required; instillations must be spaced out by 15 minutes. This constraint ensures proper drug absorption and minimizes physical interference. The regulatory labeling notes that the risk of systemic effects, such as Cushing's syndrome or adrenal suppression, resulting from increased exposure is especially important in children and patients treated with CYP3A4 inhibitors.

Mechanism of Action

Genomic Control: Suppressing Pro-Inflammatory Genes

The mechanism involves the active substance binding to the Glucocorticoid Receptor ( GR) inside the cell. This binding triggers a transrepression cascade in the cell nucleus, which directly suppresses the transcription of the genes encoding inflammatory signals, such as cytokines and chemokines. This molecular action results in a broad reduction of inflammatory signaling and modulates the local physiological response.

Biochemical Blockade of Lipid Mediators

The mechanism also includes an upstream interruption of the Arachidonic Acid Cascade. The drug indirectly inhibits the enzyme Phospholipase A2 ( PLA2), preventing the formation of inflammatory lipids like prostaglandins and leukotrienes. This biochemical blockade modulates vascular responses, resulting in the physiological consequence of decreased microvascular permeability and reduced fluid accumulation (edema) in the tissue.

Modulating Immune Cell Traffic

The drug's mechanism modulates local immune pathways by suppressing the molecules required for inflammatory cell migration and accumulation in the ocular tissue. By limiting the influx of cells like neutrophils, the mechanism constrains the inflammatory cascade, resulting in the attenuation of cellular infiltration in the target tissue.

Dosage and Administration Information

How to Use Dexafree: Administration Guidelines

Dexafree is administered via the ocular route (eye drops) and is available as a single-use container product containing no preservatives. The administration protocol is established to ensure correct usage and minimize the risk of systemic absorption and prolonged treatment.


Dosing and Treatment Duration

Guideline Instruction
Route Ocular use only, one drop per affected eye.
Initial Frequency 4 to 6 times daily.
Severe Cases Dosing may be increased to every hour.
Tapering The dose must be gradually reduced (e.g., to 3–4 times daily) as the condition improves.
Maximum Duration Treatment should generally not exceed 14 days.

Procedural Steps

Correct instillation technique is utilized, especially since the product is preservative-free and provided in single-dose units.

  1. Wash hands thoroughly before handling the container.
  2. Open the container by twisting off the top. Contents of one unit can be used for both eyes.
  3. Avoid contact between the container tip and the eye, eyelid, or any surface.
  4. Instill one drop into the affected eye by gently pulling down the lower eyelid.
  5. Immediately after instillation, press on the inner corner of the eye (nasolacrimal occlusion) for 1–2 minutes to reduce the risk of systemic absorption.
  6. The single-dose container must be discarded immediately after use, even if solution remains.

Recent Clinical Evidence

Research Evidence / Overview of Studies for Dexafree

Clinical research for Dexamethasone ophthalmic preparations has been substantially focused on its use after eye procedures, particularly cataract surgery. This area is founded upon numerous short-term Randomized Controlled Trials (RCTs). These studies were designed to investigate whether the use of Dexamethasone ophthalmic preparation is associated with changes in inflammation and pain, often comparing it to a control (placebo).

In these trials, researchers monitored the resolution of physical signs of inflammation, such as the number of inflammatory cells, alongside patient-reported outcomes describing perceived discomfort, specifically pain. Studies reported patterns in which measured outcomes evolved during the short-term intervals in participants receiving the preparation. The evidence base here is considered High, reflecting the consistency of the controlled trial data for the observed patterns. Results apply only to the populations studied, as follow-up durations were limited.

Evidence for Acute Non-Infectious Anterior Segment Inflammation

Clinical research has also explored the preparation in patients experiencing various acute, non-infectious inflammatory states affecting the superficial eye structures, such as severe allergic conjunctivitis. This evidence base is more varied, consisting of established clinical data and specific RCTs for certain acute conditions. Research examined outcomes linked to inflammatory or irritative states, tracking signs like redness and swelling. This evidence contributes to the broader landscape but is categorized as Moderate in certainty. Data quality varies across these studies, and sample sizes were modest in some older trials.

Research Gaps and Uncertainties

The research available typically focuses on short-term symptom changes and resolution of acute episodes. This means that while acute patterns were monitored, long-term effects are not fully established or were not the primary focus of the efficacy research. Furthermore, data for certain groups remain insufficient. Specifically, there is limited comprehensive research on how the preparation was evaluated in children or adolescents, and the applicability of findings to patient subgroups with significant comorbidities is uncertain. Research provides context but does not determine whether an individual will respond similarly.

Key Studies & References

  1. Public Assessment Report Decentralised Procedure - Dexamethasone phosphate 1 mg/ml eye drops, solution in single-dose container (UK/H/5450/001/DC)
  2. Rapporteur's Public Assessment Report for paediatric studies submitted in accordance with Regulation (EC) No 1901/2006 (Dexamethasone Ophthalmic Combinations)

Frequently Asked Questions (FAQ)

Common questions about Dexafree (FAQ)


Q: How quickly does Dexafree usually start working?

The official instructions indicate that the dose frequency may be adjusted rapidly once a favorable response is observed. This suggests that the preparation’s anti-inflammatory action may begin to be observed rapidly, as indicated by the rapid adjustment required for the initial dosing schedule.


Q: Are there any long-term effects of using Dexafree?

Official documents link serious safety concerns to prolonged or long-term continuous use of this preparation. These risks include the development of glaucoma (damage to the optic nerve) and the formation of a posterior subcapsular cataract. For this reason, official guidelines state that treatment duration should generally not exceed 14 days.


Q: What are the concerns about using Dexafree during pregnancy?

The use of Dexafree is generally avoided during pregnancy as a precautionary measure, according to official product information. This is based on the knowledge that corticosteroids can cross the placenta, and high-dose systemic use has been associated with effects such as growth inhibition. Although these specific effects have not been reported with ocular use, official documents advise caution.


Q: Can breastfeeding mothers use Dexafree?

Regulatory documents indicate that the preparation can be used during lactation. This is based on the rationale that the total amount of dexamethasone absorbed from the eye drops is low, minimizing the potential for transfer.


Q: Are there any reported drug-drug interactions mentioned in official documentation for Dexafree?

Official documents list known interactions with certain other medicines. These include Ritonavir and Cobicistat, which may increase the amount of corticosteroid in the body. Additionally, combining the product with phosphate-containing topical beta-blockers (used for high eye pressure) has been reported to cause local effects in the cornea.


Q: Does using Dexafree make the eyes more sensitive to light?

According to official regulatory patient materials, increased sensitivity to light, known as photophobia, is a potential adverse reaction that has been associated with the use of this eye drop preparation.


Q: Are there any specific lifestyle changes needed while using Dexafree?

Official guidelines describe that contact lenses are not to be worn during the period of use of these eye drops. Additionally, if the eye drops cause a temporary blurring of vision, patients are advised to refrain from driving or operating hazardous machinery until their vision has cleared.


Q: Is the small amount of systemic absorption from Dexafree a concern?

To minimize the amount of medicine that spreads beyond the eye, the official administration procedure includes a step to prevent or reduce systemic absorption. Official warnings highlight that the risk of systemic effects, such as adrenal suppression, is of particular concern in children and in patients taking certain other medicines (CYP3A4 inhibitors).


Q: Can I use other eye drops at the same time as Dexafree?

If other eye drops or ophthalmic solutions are required, official documents mandate a mandatory administration timing separation. Instillations of different products must be spaced out by at least 15 minutes to ensure proper absorption and minimize interference.


Q: Can Dexafree be used for conditions other than eye issues?

Official product information states that this preparation is strictly for ocular use only. Its approved indication is limited to the treatment of non-infectious inflammatory conditions that affect the front part of the eye (the anterior segment).


Q: Is Dexafree the same as regular Dexamethasone eye drops?

A critical difference is that Dexafree is formulated as a preservative-free ophthalmic solution, which is typically provided in single-dose containers. Other commercially available Dexamethasone eye drops often contain preservatives, which is a key distinguishing factor noted in official documents.


Q: Is Dexafree considered safe for children?

Regulatory documents state that the safety and efficacy of the eye drops have not been established in children under two years of age, and use in this population must be restricted. For all children, long-term continuous use is generally avoided due to the documented risk of adrenal suppression and other potential systemic effects.


Q: Is it okay to drive after using Dexafree?

The official product information notes that the eye drops have a negligible overall influence on the ability to drive and use machines. However, because the instillation may cause temporary blurring of vision, patients are specifically warned not to drive or operate hazardous machinery until their vision has fully cleared.


Q: What happens if I forget to use a dose of Dexafree?

Official product information states that following a forgotten dose, patients are instructed to not use a double dose to try and compensate. They are further instructed to continue with their regular schedule.


Q: Is it common for the inflammation not to improve while using Dexafree?

Regulatory-derived patient information advises that a patient should seek clinical review if their symptoms do not improve within a few days of starting the treatment or if the inflammation appears to worsen. This guidance indicates that a lack of observed improvement within a short period signals the need for clinical re-evaluation, as described in regulatory patient materials.


Q: Is Dexafree known to cause dry eyes?

While the most common reactions are temporary stinging and discomfort, dry eyes are listed as a potential side effect in regulatory-derived patient materials for ophthalmic dexamethasone preparations.


Q: Why is my doctor concerned about my history of herpes simplex while prescribing Dexafree?

Official documents strictly prohibit the use of this preparation in cases of active viral infections, such as Herpes Simplex Keratitis. The concern is that corticosteroids may decrease the eye's resistance to infectious agents and prolong the infection. For severe ocular diseases, steroid use may also increase the risk of corneal or scleral thinning, which can lead to perforation.


Q: What are the signs that Dexafree may be causing an issue?

Official patient resources describe certain signs that warrant immediate clinical review, such as sudden or worsening eye pain/redness, new changes in vision or sight, or signs of a serious allergic reaction, such as swelling of the face or throat.


Q: Can Dexafree be used to treat allergies in the eye?

Official regulatory information indicates that this preparation can be used as a treatment for certain severe allergic conjunctivitis (a non-infectious inflammatory condition) when other treatments have proven ineffective. Its use in this context is generally restricted to short-term therapy to manage acute inflammation.


Q: Is Dexafree used before or after eye surgery?

The clinical research and official indications for this product are focused on its role in managing post-operative inflammation. It is commonly studied and indicated for use in the eye after procedures, particularly following cataract surgery.


Q: Why is it important to use Dexafree for the full prescribed time?

Regulatory documents recommend that the dose must be gradually reduced and that patients should not stop using the medicine abruptly. The rationale is to avoid a potential relapse of the underlying condition and to ensure the full resolution of the inflammation.


Q: What kind of allergic reactions are associated with Dexafree?

The official product information lists hypersensitivity reactions as an uncommon adverse event. Signs of a serious allergic reaction, which require immediate medical review, can include swelling of the lips, mouth, throat, or tongue, and difficulty breathing.

How should Dexafree be stored and disposed of?

How to Store and Dispose of Dexafree

The storage and disposal of Dexafree (dexamethasone eye drops) must follow strict regulatory requirements, especially due to its preservative-free, single-dose formulation.

Storage Requirement Rule as Documented by Regulators
Temperature No special temperature storage conditions are required.
Protection The single-dose containers must be kept in the sachet to protect them from light.
Child Safety The medicine must be kept out of the sight and reach of children.

Stability and Handling

  • After the protective sachet is first opened, the single-dose units must be used within 15 days.
  • Each single-dose container is for single-use only; any remaining solution must be discarded immediately after use.

Disposal Instructions

To protect the environment, Dexafree must not be thrown away via household waste or wastewater. Patients should consult a pharmacist for instructions on how to properly dispose of any unused or expired medicine.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Dexafree found in:

A-Z Index: